AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope

Rock Bottom Prices May Tempt Big Pharma

 
• By Andrew McConaghie

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.

Astrazeneca
AstraZeneca's Alexion division has picked up the company at a bargain price of $68m, even while paying six times its market value.

More from Gene Therapies

More from Advanced Therapies